Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06PSU
|
|||
| Former ID |
DIB007719
|
|||
| Drug Name |
BAY1143572
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 1 | [1] | |
| Company |
Bayer healthcare pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Positive transcription elongation factor b (P-TEFb) | Target Info | Modulator | [2] |
| KEGG Pathway | HIF-1 signaling pathway | |||
| Ubiquitin mediated proteolysis | ||||
| Pathways in cancer | ||||
| Renal cell carcinoma | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02345382) Phase I Dose Escalation of BAY1143572 in Subjects With Acute Leukemia. U.S. National Institutes of Health. | |||
| REF 2 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.